



I T S
ITALIAN
THORACIC
SOCIETY



A I P O
ASSOCIAZIONE
ITALIANA
PNEUMOLOGI
OSPEDALIERI

Convegno di presentazione della versione italiana delle linee guida per la diagnosi di fibrosi polmonare idiopatica

Linee guida
ufficiali ATS/
ERS/JRS/ALAT
per la pratica
clinica

1 Febbraio
2020

Hotel
Enterprise
Milano





**Convegno di presentazione
della versione italiana delle
linee guida per la diagnosi di
fibrosi polmonare idiopatica**

**Linee guida ufficiali ATS/
ERS/JRS/ALAT
per la pratica clinica**



**1 Febbraio
2020**



**Hotel
Enterprise
Milano**

L'ALGORITMO DIAGNOSTICO


Donato LACEDONIA

Università di Foggia



Diagnosis of Idiopathic Pulmonary Fibrosis

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Ganesh Raghu, Martine Remy-Jardin, Jeffrey L. Myers, Luca Richeldi, Christopher J. Ryerson, David J. Lederer, Juergen Behr, Vincent Cottin, Sonye K. Danoff, Ferran Morell, Kevin R. Flaherty, Athol Wells, Fernando J. Martinez, Arata Azuma, Thomas J. Bice, Demosthenes Bouros, Kevin K. Brown, Harold R. Collard, Abhijit Duggal, Liam Galvin, Yoshikazu Inoue, R. Gisl Jenkins, Takeshi Johkoh, Ella A. Kazerooni, Masanori Kitaichi, Shandra L. Knight, George Mansour, Andrew G. Nicholson, Sudhakar N. J. Pipavath, Ivette Buendia-Roldán, Moisés Selman, William D. Travis, Simon Walsh, and Kevin C. Wilson; on behalf of the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society



Fisica Classica



Fisica Quantistica

Convegno di presentazione della
versione italiana delle linee guida per la
diagnosi di fibrosi polmonare idiopatica

Linee guida ufficiali
ATS/ERS/JRS/ALAT
per la pratica clinica




1 Febbraio
2020

Hotel
Enterprise
Milano




Algoritmo è un procedimento che risolve un determinato problema attraverso un numero finito di passi: elementari, chiari e non ambigui



2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)



CHD = coronary heart disease; CT = computed tomography; CTD = connective tissue disease; CTEPH = chronic thromboembolic pulmonary hypertension

**Convegno di presentazione della
versione italiana delle linee guida per la
diagnosi di fibrosi polmonare idiopatica**

Linee guida ufficiali
ATS/ERS/JRS/ALAT
per la pratica clinica

1 Febbraio
2020

Hotel
Enterprise
Milano

ITALIAN RESPIRATORY SOCIETY
SIP
SOCIETÀ ITALIANA DI
PNEUMOLOGIA

ITS
 ITALIAN
 THORACIC
 SOCIETY

AIP
ASSOCIAZIONE
ITALIANA
PNEUMOLOGO
QUEST'ANNO

American Thoracic Society

1999 Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment International Consensus Statement

THIS JOINT STATEMENT OF THE AMERICAN THORACIC SOCIETY (ATS), AND THE EUROPEAN RESPIRATORY SOCIETY (ERS) WAS ADOPTED BY THE ATS BOARD OF DIRECTORS, JULY 1999 AND BY THE ERS EXECUTIVE COMMITTEE, OCTOBER 1999

IPF is defined as a specific form of chronic fibrosing interstitial pneumonia limited to the lung and associated with the **histologic appearance** of usual interstitial pneumonia (**UIP**) on surgical (thoracoscopic or open) lung biopsy.

Convegno di presentazione della
versione italiana delle linee guida per la
diagnosi di fibrosi polmonare idiopatica

Linee guida ufficiali
ATS/ERS/JRS/ALAT
per la pratica clinica



1 Febbraio
2020

Hotel
Enterprise
Milano



Diagnosi

1999 *In the absence of a surgical lung biopsy, the diagnosis of IPF remains uncertain. However, in the immunocompetent adult...*

all

Major Criteria

- Exclusion of other known causes of ILD
- Evidence of restriction (reduced VC often with an increased FEV1/FVC ratio) and impaired gas exchange DLCO
- Bibasilar reticular abnormalities with minimal ground glass opacities on HRCT scans
- Transbronchial lung biopsy or bronchoalveolar lavage (BAL) showing no features to support an alternative diagnosis



Minor Criteria

- Age >50yr
- Insidious onset of otherwise unexplained dyspnea on exertion
- Duration of illness >3 mo
- Bibasilar, inspiratory crackles (dry or “Velcro” type in quality)


At least 3



An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

Ganesh Raghu, Harold R. Collard, Jim J. Egan, Fernando J. Martinez, Juergen Behr, Kevin K. Brown, Thomas V. Colby, Jean-François Cordier, Kevin R. Flaherty, Joseph A. Lasky, David A. Lynch, Jay H. Ryu, Jeffrey J. Swigris, Athol U. Wells, Julio Ancochea, Demosthenes Bouros, Carlos Carvalho, Ulrich Costabel, Masahito Ebina, David M. Hansell, Takeshi Johkoh, Dong Soon Kim, Talmadge E. King, Jr., Yasuhiro Kondoh, Jeffrey Myers, Nestor L. Müller, Andrew G. Nicholson, Luca Richeldi, Moisés Selman, Rosalind F. Dudden, Barbara S. Griss, Shandra L. Protzko, and Holger J. Schünemann, on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis

2011



The diagnosis of IPF is multidisciplinary


2011

TABLE 4. HIGH-RESOLUTION COMPUTED TOMOGRAPHY CRITERIA FOR UIP PATTERN

UIP Pattern (All Four Features)	Possible UIP Pattern (All Three Features)	Inconsistent with UIP Pattern (Any of the Seven Features)
<ul style="list-style-type: none"> • Subpleural, basal predominance • Reticular abnormality • Honeycombing with or without traction bronchiectasis • Absence of features listed as inconsistent with UIP pattern (see third column) 	<ul style="list-style-type: none"> • Subpleural, basal predominance • Reticular abnormality • Absence of features listed as inconsistent with UIP pattern (see third column) 	<ul style="list-style-type: none"> • Upper or mid-lung predominance • Peribronchovascular predominance • Extensive ground glass abnormality (extent > reticular abnormality) • Profuse micronodules (bilateral, predominantly upper lobes) • Discrete cysts (multiple, bilateral, away from areas of honeycombing) • Diffuse mosaic attenuation/air-trapping (bilateral, in three or more lobes) • Consolidation in bronchopulmonary segment(s)/lobe(s)

TABLE 5. HISTOPATHOLOGICAL CRITERIA FOR UIP PATTERN

UIP Pattern (All Four Criteria)	Probable UIP Pattern	Possible UIP Pattern (All Three Criteria)	Not UIP Pattern (Any of the Six Criteria)
<ul style="list-style-type: none"> • Evidence of marked fibrosis/ architectural distortion, \pm honeycombing in a predominantly subpleural/ paraseptal distribution • Presence of patchy involvement of lung parenchyma by fibrosis • Presence of fibroblast foci • Absence of features against a diagnosis of UIP suggesting an alternate diagnosis (see fourth column) 	<ul style="list-style-type: none"> • Evidence of marked fibrosis / architectural distortion, \pm honeycombing • Absence of either patchy involvement or fibroblastic foci, but not both • Absence of features against a diagnosis of UIP suggesting an alternate diagnosis (see fourth column) <p>OR</p> <ul style="list-style-type: none"> • Honeycomb changes only[†] 	<ul style="list-style-type: none"> • Patchy or diffuse involvement of lung parenchyma by fibrosis, with or without interstitial inflammation • Absence of other criteria for UIP (see UIP PATTERN column) • Absence of features against a diagnosis of UIP suggesting an alternate diagnosis (see fourth column) 	<ul style="list-style-type: none"> • Hyaline membranes* • Organizing pneumonia*[†] • Granulomas[†] • Marked interstitial inflammatory cell infiltrate away from honeycombing • Predominant airway centered changes • Other features suggestive of an alternate diagnosis





Logica Fuzzy



Convegno di presentazione della
versione italiana delle linee guida per la
diagnosi di fibrosi polmonare idiopatica

Linee guida ufficiali
ATS/ERS/JRS/ALAT
per la pratica clinica



1 Febbraio
2020

Hotel
Enterprise
Milano



I T S
ITALIAN
THORACIC
SOCIETY



AIPO
ASSOCIAZIONE
ITALIANA
PNEUMOLOGI
OSPEDALIERI

IPF suspected*		Histopathology pattern			
		UIP	Probable UIP	Indeterminate for UIP	Alternative diagnosis
HRCT pattern	UIP	IPF	IPF	IPF	Non-IPF dx
	Probable UIP	IPF	IPF	IPF (Likely)**	Non-IPF dx
	Indeterminate	IPF	IPF (Likely)**	Indeterminate***	Non-IPF dx
	Alternative diagnosis	IPF (Likely)** /non-IPF dx	Non-IPF dx	Non-IPF dx	Non-IPF dx

Convegno di presentazione della
versione italiana delle linee guida per la
diagnosi di fibrosi polmonare idiopatica

Linee guida ufficiali
ATS/ERS/JRS/ALAT
per la pratica clinica



1 Febbraio
2020

Hotel
Enterprise
Milano



Figure 8. Idiopathic pulmonary fibrosis diagnosis based upon HRCT and biopsy patterns.

**“Clinically suspected of having IPF” = unexplained symptomatic or asymptomatic patterns of bilateral pulmonary fibrosis on a chest radiograph or chest computed tomography, bibasilar inspiratory crackles, and age greater than 60 years. (Middle-aged adults [>40 yr and <60 yr], especially patients with risks for familial pulmonary fibrosis, can rarely present with the otherwise same clinical scenario as the typical patient older than 60 years.)

**IPF is the likely diagnosis when any of the following features are present:

- Moderate-to-severe traction bronchiectasis/bronchiolectasis (defined as mild traction bronchiectasis/bronchiolectasis in four or more lobes including the lingual as a lobe, or moderate to severe traction bronchiectasis in two or more lobes) in a man over age 50 years or in a woman over age 60 years
- Extensive ($>30\%$) reticulation on HRCT and an age >70 years
- Increased neutrophils and/or absence of lymphocytosis in BAL fluid
- Multidisciplinary discussion reaches a confident diagnosis of IPF.

***Indeterminate

- Without an adequate biopsy
- With an adequate biopsy

dx = diagnosis; HRCT = high-resolution

confident

diagnosis after multidisciplinary discussion and/or additional consultation.
pathic pulmonary fibrosis; UIP = usual interstitial pneumonia.

IPF guideline ATS_ERS 2000.pdf - Adobe Acrobat Reader DC

File Modifica Vista Finestra ?

Home Strumenti IPF guideline ATS_E... x

1 / 19 137%

Trova
probable
Precedente Avanti

American Thoracic Society

Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment International Consensus Statement

THIS JOINT STATEMENT OF THE AMERICAN THORACIC SOCIETY (ATS), AND THE EUROPEAN RESPIRATORY SOCIETY (ERS) WAS ADOPTED BY THE ATS E

Many acute and chronic of pulmonary inflammation referred to as interstitial chymal lung diseases. Idiopathic fibrosing alveolar idiopathic interstitial pneumonia distinct clinical disorder our understanding of the pathogenesis of lung fibrosis (1), the diagnosis and management of patients with IPF continues to


Adobe Acrobat Reader

Adobe Acrobat Reader ha completato la ricerca all'interno del documento. Non è stata trovata alcuna corrispondenza.

OK

Windows
Windows. Per attivare Windows.





Convegno di presentazione della
versione italiana delle linee guida per la
diagnosi di fibrosi polmonare idiopatica

Linee guida ufficiali
ATS/ERS/JRS/ALAT
per la pratica clinica



1 Febbraio
2020

Hotel
Enterprise
Milano



IPF guideline ATS_ERS 2018.pdf - Adobe Acrobat Reader DC

File Modifica Vista Finestra ?

Home Strumenti IPF - ATS 2011.pdf IPF guideline ATS_E... x

1 / 25 137%

Trova (35/35) probable Precedente Avanti

AMERICAN THORACIC SOCIETY DOCUMENTS

Diagnosis of Idiopathic Pulmonary Fibrosis

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Ganesh Raghu, Martine Remy-Jardin, Jeffrey L. Myers, Luca Richeldi, Christopher J. Ryerson, David J. Lederer, Juergen Behr, Vincent Cottin, Sonye K. Danoff, Ferran Morell, Kevin R. Flaherty, Athol Wells, Fernando J. Martinez, Arata Azuma, Thomas J. Bice, Demosthenes Bouros, Kevin K. Brown, Harold R. Collard, Abhijit Duggal, Liam Galvin, Yoshikazu Inoue, R. Gisli Jenkins, Takeshi Johkoh, Ella A. Kazerooni, Masanori Kitaichi, Shandra L. Knight, George Mansour, Andrew G. Nicholson, Sudhakar N. J. Pipavath, Ivette Buendía-Roldán, Moisés Selman, William D. Travis, Simon Walsh, and Kevin C. Wilson; on behalf of the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society

THIS OFFICIAL CLINICAL PRACTICE GUIDELINE OF THE AMERICAN THORACIC SOCIETY (ATS), EUROPEAN RESPIRATORY SOCIETY (ERS), JAPANESE RESPIRATORY SOCIETY (JRS), AND LATIN AMERICAN THORACIC SOCIETY (ALAT) WAS APPROVED BY THE ATS, JRS, AND ALAT MAY 2018, AND THE ERS JUNE 2018

Attiva Windows
Passa a Impostazioni PC per attivare Windows.

Convegno di presentazione della
versione italiana delle linee guida per la
diagnosi di fibrosi polmonare idiopatica

Linee guida ufficiali
ATS/ERS/JRS/ALAT
per la pratica clinica




1 Febbraio
2020


Hotel
Enterprise
Milano



2011



2018



Diagnosis of Idiopathic Pulmonary Fibrosis
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Ganesh Raghu, Martine Remy-Jardin, Jeffrey L. Myers, Luca Richeldi, Christopher J. Ryerson, David J. Lederer, Juergen Behr, Vincent Cottin, Sonye K. Danoff, Ferran Morel, Kevin R. Flaherty, Athol Wells, Fernando J. Martinez, Astar Azuma, Thomas J. Bica, Demosthenes Bours, Kevin K. Brown, Harold R. Colford, Abhijit Duggal, Liam Galvin, Yoshikazu Inoue, R. Gisi Jenkins, Takeshi Johkoh, Ella A. Kazerooni, Masanori Kitaichi, Shandra L. Knight, George Mansour, Andrew G. Nicholson, Sudhakar N. J. Pipavath, Ivette Buendia-Roldán, Moisés Selman, William D. Travis, Simon Walsh, and Kevin C. Wilson; on behalf of the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society

This official clinical practice guideline of the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and Latin American Thoracic Society (ALAT) was approved by the ATS, JRS, and ALAT May 2018, and the ERS June 2018

For patients with newly detected ILD of apparently unknown cause who are clinically suspected of having IPF, **we suggest MDD for diagnostic decisionmaking**

“**1,000** patients who undergo diagnostic decision-making, SDD and MDD will derive the same diagnosis in **700** patients and different diagnoses in **300** patients. If one accepts MDD as the reference standard, then as many as 300 patients will be potentially subject to incorrect therapy, delayed therapy, or unnecessary additional diagnostic testing”

“For patients with newly detected ILD of apparently unknown cause who are clinically suspected of having IPF, **we suggest MDD for diagnostic decisionmaking**
(*conditional recommendation, very low quality of evidence*)



Esperienza

Convegno di presentazione della
versione italiana delle linee guida per la
diagnosi di fibrosi polmonare idiopatica

Linee guida ufficiali
ATS/ERS/JRS/ALAT
per la pratica clinica




1 Febbraio
2020


Hotel
Enterprise
Milano



**Diagnosi
Precoce**



**Diagnosi
Certa**



Convegno di presentazione della
versione italiana delle linee guida per la
diagnosi di fibrosi polmonare idiopatica

Linee guida ufficiali
ATS/ERS/JRS/ALAT
per la pratica clinica



1 Febbraio
2020

Hotel
Enterprise
Milano

